Precision medicine approaches have led to tremendous successes in oncology and now we have the insights to be at the forefront of developing precision medicines to transform the treatment landscape for neuropsychiatry said Mitsuyuki Matsumoto Arialys scientific founder and chief scientific officer in a statement